(USD) | Feb 2024 | Q/Q |
---|---|---|
Revenue | 18.3MM | +26% |
Gross Profit | 13.2MM | +34% |
Cost Of Revenue | 5.1MM | +9% |
Operating Income | 4.4MM | - |
Operating Expenses | 8.8MM | -1% |
Net Income | 4MM | - |
R&D | 1.3MM | +8% |
G&A | 5.5MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
You may have heard about GPT-4 Turbo, Gemini, Llama or X’s (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town. It’s called Claude, created by Anthropic. The company recently released Claude 3 models and claims its premium “Opus” model is smarter than all other AI bots. Many people have touted it as the most intelligent AI available right now. Moreover, it has access to events up to August 2023, making it more up-to-date than other models. Could Cl
For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.
Simulations Plus, Inc. ( NASDAQ:SLP ) investors will be delighted, with the company turning in some strong numbers with...
Simulations Plus ( NASDAQ:SLP ) Second Quarter 2024 Results Key Financial Results Revenue: US$18.3m (up 16% from 2Q...
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2024 Earnings Call Transcript April 3, 2024 Simulations Plus, Inc. beats earnings expectations. Reported EPS is $0.1983, expectations were $0.18. Simulations Plus, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. And welcome to […]
LANCASTER, Calif., April 04, 2024--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.
Simulations Plus' (SLP) second-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments.
Q2 2024 Simulations Plus Inc Earnings Call
Strong Revenue Growth and Dividend Declaration in Q2 Fiscal 2024
Simulations Plus (SLP) delivered earnings and revenue surprises of 11.11% and 7.24%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?